Caixa Innvierte BioMed II

ABAC Therapeutics Announces €16 Million Series A to Develop Therapeutic Solutions to Fight Antibiotic-Resistant Bacteria

ABAC Therapeutics (ABAC), a leader in pathogen-specific antibiotics, announced today the closing of a €16 million Series A round. The financing was led by Pontifax with participation from the Global Health Science Fund (jointly established by Quark Venture Inc. and GF Securities), Caixa Capital Risc, Debiopharm Innovation Fund and the existing investor Ferrer.

| Read more |

QIAGEN enters into agreement to acquire STAT-Dx, a Caixa Capital Risc portfolio company

STAT-Dx, a privately-held company developing the next generation of multiplex diagnostics for one-step, fully integrated molecular analysis of common syndromes. The system was unveiled in April 2017 at the European Congress of Clinical Microbiology (ECCMID) and received a first CE-IVD marking in January 2018.

| Read more |

MedLumics, a company owned by “la Caixa” and Ysios Capital, closes a financing round of 34.4 million euros

• Medlumics has closed a round of financing round of 34,4 million euros to bring their main product into the market, AblaView, an atrial fibrillation treatment in the field of cardiac arrhythmias.
• Medlumics is a company dedicated to medical technology for the treatment of cardiac diseases, with products based on photonic energy.
• Caixa Capital Risc and Ysios Capital invested in Medlumics in 2012 to support the company in its development.
• This has been the largest round in the history of the medical technology industry in Spain, and one of the largest in Europe.

| Read more |

Minoryx Therapeutics Initiates Phase 1 clinical trial of MIN-102

MIN-102, a differentiated PPAR agonist, targets X-linked Adrenoleukodystrophy (X-ALD), a life threatening orphan CNS disease with a high unmet medical need

– Trial will assess pharmacokinetics, safety and tolerability of MIN-102 after administration of single and multiple ascending doses in healthy volunteers.

| Read more |

(Español) Minoryx Therapeutics nombra al Dr. Uwe Meya como Director Médico

(Español) El Dr. Meya, especialista en trastornos neurológicos, dirigirá el desarrollo clínico del principal candidato de Minoryx, el MIN-102, para la X-ALD.

| Read more |